Scemblix (Asciminib) for Myeloproliferative Neoplasms

Overview
Scemblix is approved by the U.S. Food and Drug Administration (FDA) to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. This includes newly diagnosed cases, previously treated cases, and cases with the T315I mutation (variation). Scemblix is also known by its drug name, asciminib.

Scientists believe that Scemblix works by inhibiting the activity of BCR-ABL1, a protein that promotes the growth of leukemia cells. By blocking this protein, Scemblix may help reduce the number of cancerous cells in people with CML.

How do I take it?
Prescribing information states that Scemblix is taken orally in tablet form. For Ph+ CML in the chronic phase, it is typically taken once daily at a higher dose or twice daily at a lower dose. For individuals with the T315I mutation, it’s generally taken at a higher dose taken twice daily. It is advised to avoid eating for at least two hours before and one hour after taking Scemblix. The tablets should be swallowed whole without breaking, crushing, or chewing. Scemblix should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Scemblix include musculoskeletal pain, rash, fatigue, upper respiratory tract infections, headache, abdominal pain, and diarrhea. Laboratory tests may also reveal decreased counts of white blood cells, platelets, and lymphocytes; increased levels of liver enzymes (ALT, AST), lipase, cholesterol, uric acid, and triglycerides; and decreased calcium and hemoglobin levels.

Rare but serious side effects may include severe myelosuppression (reduced blood cell production), pancreatic toxicity (potential pancreas damage), hypertension (high blood pressure), hypersensitivity reactions (allergic responses), and cardiovascular toxicity (heart and blood vessel complications). Scemblix can also cause fetal harm.

For more information about this treatment, visit:

Label: Scemblix — Asciminib Tablet, Film Coated — DailyMed